Why is Savara stock plunging today?
Savara (SVRA) stock fell 21.7% pre-market after the FDA delayed its decision on molgramostim, a treatment for a rare lung disease, without setting a new timeline. The stock had risen to $5.21 ahead of the expected decision. Analysts maintain Buy ratings with targets of $10-$11, but uncertainty looms. The broader market decline also pressured the stock, which traded at $4.08, near its 52-week low.
How this was made
The 30-second read
Why it matters
The unexpected delay removes the catalyst that drove recent gains, likely leading to continued downside pressure.
Market read
The news directly caused a >20% pre‑market drop, making it a high‑impact, actionable event for traders.
What to watch
Potential positive data from European/UK regulators could mitigate U.S. delay risk.
Background
Savara had rallied on expectations of FDA approval for its inhaled molgramostim therapy for autoimmune pulmonary alveolar proteinosis.
Ticker impact
FDA announced it will not meet the Nov 22 PDUFA target for Savara's molgramostim BLA, causing a 21.7% pre‑open plunge.
downward pressure as investors price in the open‑ended regulatory timeline
A 20%+ pre‑market drop on a fresh regulatory setback is a strong sell signal for a clinical‑stage biotech.
Market effects
Biotech stocks with pending FDA decisions may face broader weakness.
Nasdaq down 2.1%, S&P 500 down 1.1% as risk‑off sentiment spreads.
Limited to U.S. biotech sector; no immediate global macro impact.
Counterpoint
If Savara secures a new FDA target date soon, the stock could rebound sharply.
Key entities
- companySavara Inc.
Clinical‑stage biopharma developing molgramostim.
- regulatorU.S. Food and Drug Administration
Agency responsible for approving the BLA.


